Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
6.04
-0.04 (-0.66%)
At close: Jan 2, 2026, 4:00 PM EST
6.04
0.00 (0.00%)
After-hours: Jan 2, 2026, 4:10 PM EST
Exagen Revenue
Exagen had revenue of $17.24M in the quarter ending September 30, 2025, with 37.87% growth. This brings the company's revenue in the last twelve months to $63.60M, up 14.08% year-over-year. In the year 2024, Exagen had annual revenue of $55.64M with 5.89% growth.
Revenue (ttm)
$63.60M
Revenue Growth
+14.08%
P/S Ratio
1.94
Revenue / Employee
$295,809
Employees
215
Market Cap
136.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55.64M | 3.09M | 5.89% |
| Dec 31, 2023 | 52.55M | 6.99M | 15.33% |
| Dec 31, 2022 | 45.56M | -2.74M | -5.66% |
| Dec 31, 2021 | 48.30M | 6.32M | 15.07% |
| Dec 31, 2020 | 41.98M | 1.59M | 3.93% |
| Dec 31, 2019 | 40.39M | 7.95M | 24.50% |
| Dec 31, 2018 | 32.44M | 5.63M | 21.01% |
| Dec 31, 2017 | 26.81M | 8.86M | 49.38% |
| Dec 31, 2015 | 17.95M | 6.28M | 53.87% |
| Dec 31, 2014 | 11.66M | 8.61M | 281.77% |
| Dec 31, 2013 | 3.06M | 2.13M | 229.91% |
| Dec 31, 2012 | 926.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XGN News
- 7 weeks ago - Exagen Inc. to Participate in Fourth Quarter Investor Conferences - GlobeNewsWire
- 2 months ago - Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Exagen Inc. Reports Strong Q3 2025 Results - GlobeNewsWire
- 2 months ago - Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence - GlobeNewsWire
- 2 months ago - Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewsWire
- 5 months ago - Exagen Inc. to Participate in Third Quarter Investor Conferences - GlobeNewsWire
- 5 months ago - Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Exagen Inc. Reports Strong Q2 2025 Results - GlobeNewsWire